These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia. Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205 [TBL] [Abstract][Full Text] [Related]
16. beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects. Lehmann H; Nair NP; Kline NS Am J Psychiatry; 1979 Jun; 136(6):762-6. PubMed ID: 220889 [TBL] [Abstract][Full Text] [Related]
17. Intravenous naloxone administration in schizophrenia and affective illness. Davis GC; Bunney WE; DeFraites EG; Kleinman JE; van Kammen DP; Post RM; Wyatt RJ Science; 1977 Jul; 197(4298):74-7. PubMed ID: 325650 [TBL] [Abstract][Full Text] [Related]
18. beta-Endorphin and schizophrenia. Berger PA; Watson SJ; Akil H; Elliott GR; Rubin RT; Pfefferbaum A; Davis KL; Barchas JD; Li CH Arch Gen Psychiatry; 1980 Jun; 37(6):635-40. PubMed ID: 7387335 [TBL] [Abstract][Full Text] [Related]
19. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278 [TBL] [Abstract][Full Text] [Related]